APA (7th ed.) Citation

SA, P., CL, H., CA, F., S, C., I, B., PA, C., . . . GI, S. (2019). Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors. JNCI cancer spectrum, 4(2), pkz093. https://doi.org/10.1093/jncics/pkz093

Chicago Style (17th ed.) Citation

SA, Piha-Paul, et al. "Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors." JNCI Cancer Spectrum 4, no. 2 (2019): pkz093. https://doi.org/10.1093/jncics/pkz093.

MLA (9th ed.) Citation

SA, Piha-Paul, et al. "Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors." JNCI Cancer Spectrum, vol. 4, no. 2, 2019, p. pkz093, https://doi.org/10.1093/jncics/pkz093.